Motion Sickness related Route Profiling for Evaluation of the Sensory Conflict in Real-Driving Studies.

The risk for passengers of an automated vehicle to suffer from motion sickness symptoms increases while performing non-driving tasks. Motion sickness, whether at sea, in the air, in a car or in virtual reality, has been studied for years, but the specific motion patterns of different vehicles and the individual physiology of passengers complicate the definition of general applicable models. Technical progress in vehicles, e.g. the development of the chassis or general digitalization, is constantly changing the influences and marginal effects of motion sickness. In recent years, increasing number of investigations concentrated on the influencing factors on motion sickness. However, the relation between emesis and vehicle dynamics itself is predominantly inadequately presented. Therefore, the results can poorly be incorporate in mathematical models of the sensory conflict theory established as leading theory in the research community. In our research, we suggest a method to prepare and present route and driving information to increase the transparency of real-world driving experiments. We used determined position-based spectrograms to simplify the understanding of the provoked acceleration as well as frequency, known as important motion sickness trigger. Standardized use of this method would support review articles about driving experiments and thus support research regarding motion sickness prediction and occurrence in vehicles.

Ovarian tumor cells express a novel multi-domain cell surface serine protease.

Serine proteases serve many functions in normal biological processes. These functions are often usurped by cancer cells to allow progression of tumors by increasing the growth and metastatic potential of the neoplasia. Here, we have used a polymerase chain reaction (PCR)-based strategy to clone Tumor Associated Differentially-expressed Gene-12 (TADG-12), a new serine protease from ovarian carcinoma. This technique also revealed a variant splicing form of TADG-12 that could lead to a truncated protein product. Semi-quantitative PCR showed that TADG-12 is overexpressed in 41 of 55 ovarian cancer specimens relative to normal expression, and the variant form, TADG-12V is found at increased levels in 8 of 22 carcinomas examined. Northern blot revealed three transcripts, the largest of which is approximately 2.4 kb. An ovarian tumor cDNA library was screened, and the entire cDNA of TADG-12 has been identified. This sequence encodes a putative protein of 454 amino acids which includes a potential transmembrane domain, an LDL receptor-like domain, a scavenger receptor cysteine-rich domain, and a serine protease domain. These features imply that TADG-12 will be at the cell surface, and it may be useful as a molecular target for therapy or a diagnostic marker.

Fronto-ocular syndrome: newly recognized trigonocephaly syndrome.

We describe an apparently unique disorder, Fronto-Ocular syndrome, present in a mother and her two daughters, and comprising trigonocephaly due to coronal and metopic craniosynostosis, ocular hypotelorism, ocular proptosis and ptosis, epicanthal folds, hypoplastic supraorbital ridges, elevated nasal bridge, thin philtrum, high-arched palate and a narrow bifrontal region. Both daughters have glabellar capillary hemangiomas, a congenital heart defect and mild developmental disabilities. Review of the literature failed to disclose any syndrome with similar findings. It is likely that this disorder represents an autosomal dominant condition, that arose as a new mutation in the mother. Mutational analysis of fibroblast growth factor receptor (FGFR) 1 and FGFR2 failed to identify the molecular basis of the disorder.